StreetInsider.com News Articles

Oil Above $100 Puts Penny Stocks in Focus

Fri, 23 Oct 2026 11:59:10 -0400

DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — With U.S. crude hovering above $100 a barrel, investors are looking beyond the energy trade for smaller companies with potentially transformative technologies and upcoming commercial catalysts. 247 Market News is tracking Kraig Biocraft Laboratories (OTCQB: KBLB), Hyperscale Data (NYSEAMERICAN: GPUS), Lucid Diagnostics (NASDAQ: LUCD), and 22nd Century Group (NASDAQ: XXII).

KBLB Moves Spider Silk Toward Commercial Applications

Kraig Biocraft Laboratories (OTCQB: KBLB) has taken a notable step toward commercialization, recently shipping its first commercial order of recombinant spider silk yarn to

Oil Above $100 Puts Penny Stocks in Focus

Fri, 23 Oct 2026 11:59:10 -0400

KBLB Moves Spider Silk Toward Commercial Applications

Kraig Biocraft Laboratories (OTCQB: KBLB) has taken a notable step toward commercialization, recently shipping its first commercial order of recombinant spider silk yarn to

Oil Above $100 Puts Penny Stocks in Focus

Fri, 23 Oct 2026 11:59:10 -0400

KBLB Moves Spider Silk Toward Commercial Applications

Kraig Biocraft Laboratories (OTCQB: KBLB) has taken a notable step toward commercialization, recently shipping its first commercial order of recombinant spider silk yarn to

Oil Above $100 Puts Penny Stocks in Focus

Fri, 23 Oct 2026 11:59:10 -0400

KBLB Moves Spider Silk Toward Commercial Applications

Kraig Biocraft Laboratories (OTCQB: KBLB) has taken a notable step toward commercialization, recently shipping its first commercial order of recombinant spider silk yarn to

Form 8-K Lucid Diagnostics Inc. For: Oct 21

Thu, 22 Oct 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20261022/27223181.html

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

Thu, 22 Oct 2026 16:20:00 -0400

Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate

Series C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial acceleration

NEW YORK, Oct. 22, 2026 /PRNewswire/

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

Thu, 22 Oct 2026 16:20:00 -0400

Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate

Series C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial acceleration

NEW YORK, Oct. 22, 2026 /PRNewswire/

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

Thu, 22 Oct 2026 16:20:00 -0400

Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate

Series C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial acceleration

NEW YORK, Oct. 22, 2026 /PRNewswire/

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

Thu, 22 Oct 2026 16:20:00 -0400

Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate

Series C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial acceleration

NEW YORK, Oct. 22, 2026 /PRNewswire/

Form 8-K Lucid Diagnostics Inc. For: Oct 12

Fri, 16 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261016/27198279.html

Form 8-K Lucid Diagnostics Inc. For: Sep 22

Tue, 22 Sep 2026 09:07:00 -0400

si-local-file:///var/storage/secattach/20260922/27088821.html

Lucid Diagnostics gets coding and billing updates for esophageal tests

Tue, 22 Sep 2026 07:57:04 -0400

Lucid Diagnostics Inc. (Nasdaq: LUCD), a subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced developments across three regulatory and coding proceedings affecting its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, according to a company press release.

A Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests, convened by the Centers for Medicare & Medicaid Services (CMS) on September 15-16, recommended maintaining the original gapfill payment basis for EsoGuard under the Clinical Laboratory Fee Schedule, using PLA code 0114U. The payment rate has been in effect since the CY2021 CLFS Update. CMS is expected to issue final determinations in November following

Lucid Diagnostics gets coding and billing updates for esophageal tests

Tue, 22 Sep 2026 07:57:04 -0400

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Tue, 22 Sep 2026 07:55:00 -0400

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule

AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck

Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Tue, 22 Sep 2026 07:55:00 -0400

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule

AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck

Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Tue, 22 Sep 2026 07:55:00 -0400

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule

AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck

Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Tue, 22 Sep 2026 07:55:00 -0400

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule

AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck

Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business